MDS session is next. Dr Ana Carvalhosa with a case presentation #BSH2017
Additive effects of driver mutations in MDS on leukaemogenesis: more mutns = increased risk of leukaemia #BSH2017
Relatively new terms emerging in MDS: ICUS, CHOP, CCUS #BSH2017
45% of those over 60y have at least 1 somatic mutation but only 4% of those w a mutn develop haem malignancy #BSH2017
ICUS = idiopathic cytopenias of undetermined signifance - little dysplasia, no clone (or not tested) #BSH2017
CHIP = clonal haemopoiesis of indeterminate potential: 0.5-1% risk per yr of transformation #BSH2017
CCUS = clonal cytopenia of undetermined significance: usually 2 or more clones but are the clone(s) responsible for cytopenias? #BSH2017
Next up Dr Guilllermo Garcia-Manero from the MD Anderson on treating hypomethylating agent failure in MDS #BSH2017
Some mutations predict better response to hypomethylating agents #BSH2017
Outcomes of pts who fail hypomethylating agents have prognosis akin to pts w AML #BSH2017
Non response versus relapse after HMA may predict for response to subsequent treatments - shown in Rigosertib study #BSH2017
Conventional chemotherapy (e.g. Clofarabine and LD araC) only useful in those with no mutations #BSH2017
FLT3 and RAS mutations v important in MDS and can signify imminent transformation #BSH2017
Adding in FLT3 inhibitor to HMA can improve responses in those with new FLT3 mutations #BSH2017
Switching between aza and decitabine not conventionally thought to be worthwhile #BSH2017
Second generation HMA guadecitabine now in phase III clinical studies &many other promising agents in development #BSH2017
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.